Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Fallopian Tube Neoplasms 4Brenner Tumor 4Colorectal Neoplasms 3Colonic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Tongue Neoplasms 1Stroke 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pulmonary Disease, Chronic Obstructive 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Lymphoid Interstitial Pneumonia 1Kidney Failure, Chronic 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Endometrial Neoplasms 1Diabetes Mellitus 1Coronary Artery Disease 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 2ribociclib 1exemestane 1durvalumab 1Taxes 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anatomic Stage II Breast Cancer AJCC v8 × Disulfides × Clear all
NCT06058377 2026-06-03

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡